Focus on new targets and innovative NCE drugs
Metagone Biotechnology Co., Ltd. was established on January 22, 2015, focusing on the development of new targets, the first-in-class innovative drug in the market. After Proof of Concept in clinical, exclusive license or strategic alliance to partners to obtain revenue. R&D product pipelines include:

1.MG-D-1509 pan-cancer drug: suitable for cancers with biological target pDAPK, ex: breast cancer, liver cancer, lung cancer, colorectal cancer, kidney cancer, oral cancer, skin cancer and others.

2.MG-S-2525 rare and respiratory diseases: MAK3K19 inhibitor is suitable for idiopathic pulmonary fibrosis, pulmonary fibrosis combined with emphysema, chronic pulmonary obstruction.

3.Metastasis: Meta1 inhibitors control early metastasis of cancer cells.

MG pan-cancer First in Class－new combination anticancer drug
MG pan-cancer drugs (MG-D-1509, MG-D-1609) are novel combination and MoA that allosterically target to c-Raf and specifically associate with the pDAPK of tumor cells leaving mitochondria produce high amounts of ROS and subsequent pDAPK dissociation, belong First-in-Class new drug. The Phase I clinical trial of MG-D-1509 was completed in 2020. 01. For patients with solid tumors, there are no obvious related adverse effects. Subjects in any dose group did not encounter DLT during the evaluation period, so MTD is the highest dose of 750 mg BID MG005 + 200 mg QD Nexavar®.

The R&D team optimized and improved MG005 to MG010, which became MG-D-1609. Linked to the MG-D-1509 clinical phase I data file, MG-D-1609 was approved by the Australian HREC and RGO in September 2019 to perform clinical I/II phase trials for liver, lung, kidney, and colorectal cancers. A Safety Review Committee will be held in August 2020. It is expected that the phase I clinical trials will be completed in Q4 2020 and the phase II clinical trials will be completed in Q3 2021. To accumulated good and good quality clinical data, Metagone Biotech is confident that we can accelerate the international license deal.

MG-S-2525 first-in-class IPF/CPFE/COPD drug
MG-S-2525 small molecule new drug can inhibit the novel protein kinase MAP3K19, control the upstream inflammation generation of pulmonary fibrosis and emphysema. In the bronchoalveolar lavage macrophages of IPF patients, the overexpression of MAP3K19 can be analyzed. Meanwhile, inhibition of MAP3K19 resulted in a significant decrease in the transcription of IPF-related genes, and its expression was related to the pathology of IPF. In IPF animal models, prophylactic or therapeutic administration of MG-S-2525 can greatly reduce pulmonary fibrosis. Treatment MAP3K19 inhibitors also reduced the cigarette-induced emphysema index. Because MAP3K19 mainly appears in the lungs and trachea, MAP3K19 can also be used as an ideal target for the treatment of CPFE (combined with pulmonary fibrosis and emphysema).

The new drug MG-S-2525 completed the phase I clinical trials in Taiwan and obtained the US FDA orphan drug designation. It is currently preparing for the pilot study for CPFE phase II in clinical. There is currently no drug available for CPFE treatment. There will be huge unmet medical needs and vast international therapeutic opportunity.